World
LA NYC São Paulo London Paris Lagos Dubai Delhi Singapore Tokyo Sydney
Pulse
English · Not set Change ▾

Live scores ticker: Off · Turn on

Markets ticker: Off · Turn on

Saved in a cookie on this device (and in your account when you are logged in). We never store your IP address.

Entities › name

Parkinson

23 headlines · 18 outlets · 2005-02-25 → 2026-10-06 · Wikipedia ↗ · 🔒 Follow

Latest coverage

  • Press releases
  • Country: United States

Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson’s Disease and Exploration of Strategic Options to Maximize Shareholder Value

First Patient Dosed with JOTROL ™ Marks Major Clinical Milestone for Jupiter Neurosciences’ Phase 2a Study Evaluating Safety, Pharmacokinetics and Biomarkers of JOTROL ™ in Patients with Parkinson’s Disease

  • Press releases
  • Country: United States

Parkinson's Disease Market Poised for Expansion During the Forecast Period (2026-2036) Amid JUVMO Approval and Emerging Therapeutic Innovations | DelveInsight

The Parkinson's disease market is expected to grow steadily, driven by the recent approval of AbbVie's JUVMO along with the rising prevalence of the disease, particularly among the aging population. Increasing disease awareness, improved diagnosis, and advances in symptomatic and...

  • Press releases
  • Country: United States

Cala Announces Nationwide Launch of its Next Generation TAPS Therapy Wearable for Essential Tremor and Parkinson's Disease Further Optimizing Meaningful Outcomes for More Patients

The Cala kIQ Plus System, cleared by FDA earlier this year, is the first and only wearable neuromodulation device for hand tremor that provides multiple therapy modes and adaptive calibration designed to optimize tremor relief and personalize treatment Cala is showcasing the Cala kIQ Plus...

  • Press releases
  • Country: United States

Lundbeck presents Phase Ib data for Lu AF28996 in advanced Parkinson's disease, as Phase II trial begins

Results from an 18-week, open-label Phase Ib trial of investigational Lu AF28996 in people with advanced Parkinson's disease are being presented at MDS 2026 The trial provided initial safety and tolerability data for Lu AF28996, with most treatment-emergent adverse events reported as mild...

  • Press releases
  • Country: United States

Lundbeck presents Phase Ib data for Lu AF28996 in advanced Parkinson's disease, as Phase II trial begins

Results from an 18-week, open-label Phase Ib trial of investigational Lu AF28996 in people with advanced Parkinson's disease are being presented at MDS 2026 The trial provided initial safety and tolerability data for Lu AF28996, with most treatment-emergent adverse events reported as mild...

Explore

News

📈Trending💹Markets🌍Map🎵Music🍿Entertainment📍Near you🏳️Countries🏷️Topics🗞️Sources👤People & places

Watch & listen

📺Live TV🎬Videos🎙️Podcasts📦Offline pack

Understand

⚖️Perspectives🧩Same story🔁What changed🏁Who's first🌐Web trends❓Why it's trending🔗Compare an article

Explore

🗓️Timeline📜On this day⏳Time Machine🐇Rabbit hole🧠Daily quiz📰Front page

Join

🔑Log in🍌Sign up 📲Notifications🍌Calm mode

Banana News

0 paying members keep Banana News going

⭐Pricingℹ️About

Banana News Single Banana

Upgrade to unlock this

See plans Log in

Free accounts get fresh bananas every day. Cancel anytime · pay by card or USDC on Base · compare all plans

↑↓ move · ↵ go · ? shortcuts

Keyboard shortcuts

Move

j / k next / previous story

o or ↵ open original

d story details

b bookmark

Go

g h home · g f front page

g t timeline · g y time machine

g b briefing · g p perspectives

g m map · g o on this day

g r rabbit hole · g w wrapped

Everywhere

/ search

Ctrl/⌘ K command palette

t cycle theme

? this help · Esc close

Shortcuts never fire while you are typing, and are off when you hold Ctrl, Alt or ⌘.